| SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion P Mlcochova, SA Kemp, MS Dhar, G Papa, B Meng, IATM Ferreira, R Datir, ... Nature 599 (7883), 114-119, 2021 | 1201 | 2021 |
| Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift E Cameroni, JE Bowen, LE Rosen, C Saliba, SK Zepeda, K Culap, ... Nature 602 (7898), 664-670, 2022 | 1104 | 2022 |
| SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern M McCallum, J Bassi, A De Marco, A Chen, AC Walls, J Di Iulio, ... Science 373 (6555), 648-654, 2021 | 508 | 2021 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 424 | 2021 |
| Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70 SA Kemp, B Meng, IA Ferriera, R Datir, WT Harvey, G Papa, S Lytras, ... BioRxiv, 2020.12. 14.422555, 2020 | 245 | 2020 |
| The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 AL Cathcart, C Havenar-Daughton, FA Lempp, D Ma, MA Schmid, ... biorxiv, 2021.03. 09.434607, 2021 | 204 | 2021 |
| Broad sarbecovirus neutralization by a human monoclonal antibody MA Tortorici, N Czudnochowski, TN Starr, R Marzi, AC Walls, F Zatta, ... Nature 597 (7874), 103-108, 2021 | 202 | 2021 |
| Imprinted antibody responses against SARS-CoV-2 Omicron sublineages YJ Park, D Pinto, AC Walls, Z Liu, A De Marco, F Benigni, F Zatta, ... Science 378 (6620), 619-627, 2022 | 151 | 2022 |
| SARS-CoV-2 B. 1.617. 2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough P Mlcochova, S Kemp, MS Dhar, G Papa, B Meng, S Mishra, C Whittaker, ... | 141* | 2021 |
| SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies I Ferreira, R Datir, G Papa, S Kemp, B Meng, P Rakshit, S Singh, ... BioRxiv, 2021 | 96 | 2021 |
| Yes‐associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice MA Kowalik, C Saliba, M Pibiri, A Perra, GM Ledda‐Columbano, I Sarotto, ... Hepatology 53 (6), 2086-2096, 2011 | 94 | 2011 |
| Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration. SARS-CoV-2 B. 1.617. 2 … P Mlcochova, SA Kemp, MS Dhar, G Papa, B Meng, I Ferreira, R Datir, ... Nature 599 (7883), 114-9, 2021 | 86 | 2021 |
| Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation R Drago-Ferrante, F Pentimalli, D Carlisi, A De Blasio, C Saliba, ... Oncotarget 8 (17), 28939, 2017 | 64 | 2017 |
| Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options G Grech, S Baldacchino, C Saliba, MP Grixti, R Gauci, V Petroni, ... Tumor Biology 37, 11691-11700, 2016 | 63 | 2016 |
| Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720 S Baldacchino, C Saliba, V Petroni, AG Fenech, N Borg, G Grech Epma Journal 5, 1-9, 2014 | 54 | 2014 |
| A loop involving NRF2, miR‐29b‐1‐5p and AKT, regulates cell fate of MDA‐MB‐231 triple‐negative breast cancer cells A De Blasio, R Di Fiore, G Pratelli, R Drago‐Ferrante, C Saliba, ... Journal of Cellular Physiology 235 (2), 629-637, 2020 | 43 | 2020 |
| Neutralization, effector function and immune imprinting of Omicron variants A Addetia, L Piccoli, JB Case, YJ Park, M Beltramello, B Guarino, H Dang, ... Nature 621 (7979), 592-601, 2023 | 42 | 2023 |
| Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients J Bassi, O Giannini, C Silacci-Fregni, L Pertusini, P Hitz, T Terrot, ... PLoS One 17 (2), e0263328, 2022 | 26 | 2022 |
| Vitamin D supplementation in systemic lupus erythematosus: relationship to disease activity, fatigue and the interferon signature gene expression R Magro, C Saliba, L Camilleri, C Scerri, AA Borg BMC rheumatology 5, 1-8, 2021 | 23 | 2021 |
| Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants A Addetia, L Piccoli, JB Case, YJ Park, M Beltramello, B Guarino, H Dang, ... Biorxiv, 2023.01. 17.523798, 2023 | 22 | 2023 |
